Access cutting-edge primary aldosteronism treatment through this clinical trial at a research site in San Francisco. Study-provided care at no cost to qualified participants.
Quick Self-Assessment
See if you qualify for this San Francisco location
Preparing your pre-screening questions…
Access primary aldosteronism specialists at no cost
This study follows strict safety protocols and ethical guidelines
All study-related primary aldosteronism treatment provided free
Check if you qualify for this primary aldosteronism clinical trial in San Francisco, CA
No-Cost Study Care
Local to San Francisco
Convenient for CA residents
Cutting-Edge Treatment
Access to innovative therapies
Expert Medical Care
Close monitoring by specialists
Possible Compensation*
For time and travel
*Compensation varies by study. Confirm details with coordinator.
This is a Phase III, multicentre, randomised, double-blind, placebo-controlled, parallel-group study to evaluate the safety, tolerability, and efficacy of baxdrostat versus placebo, on the reduction of Seated Blood Pressure (SBP) and unsuppression of Plasma Renin Activity (PRA) in approximately 180 participants ≥ 18 years of age with Primary Aldosteronism (PA), with or without prior treatment with Mineralocorticoid Receptor Antagonists (MRAs) or potassium-sparing diuretics. Baxdrostat (or place
Sponsor: AstraZeneca
Yes, this clinical trial (NCT07007793) has an active research site in San Francisco, CA that is currently enrolling participants.
Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.
Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.
Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.
If you're searching for primary aldosteronism treatment options in San Francisco, CA, this clinical trial (NCT07007793) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our San Francisco research site is actively enrolling participants for this clinical trial. You'll receive care from experienced primary aldosteronism specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.